Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ALE1
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Alesta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
1cBio, Alesta Sign Global License for Small Molecule in Hypophosphatasia
Details : Alesta will develop, commercialize, and manufacture OC-1 (also known as ALE1), an orally active therapeutic candidate for hypophosphatasia (HPP).
Product Name : OC-1
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : ALE1
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Alesta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement